home / stock / vtgn / vtgn news

VTGN News and Press, VistaGen Therapeutics Inc. From 06/20/19

Stock Information
Company Name: VistaGen Therapeutics Inc.
Stock Symbol: VTGN
Market: NASDAQ
Website: vistagen.com
Menu
VTGN VTGN Quote VTGN Short VTGN News VTGN Articles VTGN Message Board
Get VTGN Alerts

News, Short Squeeze, Breakout and More Instantly...
VTGN - VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential For Treating Levodopa-Induced Dyskinesia In Patients With Parkinson's Disease, Without The Psychological Side Effects And Safety Concerns Of Amantadine

Significant reduction of levodopa-induced dyskinesia by AV-101 observed in "gold standard" MPTP non-human primate model of Parkinson's disease, while maintaining antiparkinsonian activity of levodopa and without causing amantadine-like adverse effects SOUTH SAN FRANCISCO, CA / ACCESSWIRE...
VTGN - VistaGen Announces Positive Preclinical Data Supporting AV-101's Potential for Treating Neuropathic Pain Comparable to Pregabalin (Lyrica(R)), without its Side Effects

New preclinical data involving pregabalin are consistent with peer-reviewed data involving gabapentin previously published in The Journal of Pain SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 30, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company ...

VTGN - VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 7, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet ne...

VTGN - Healthcare tops midday movers

Gainers:  Diffusion Pharmaceuticals (NASDAQ: DFFN ) +49% . ARCA biopharma (NASDAQ: ABIO )  +47% . Digimarc Corporation (NASDAQ: DMRC ) +46% . Hudson Technologies (NASDAQ: HDSN ) +23% . InspireMD (NYSEMKT: NSPR ) +17% . Materion Corporation (NYSE: MTRN ) +16% . Precipio (NASD...
VTGN - VistaGen's AV-101 flunks mid-stage depression study; shares down 45%

Thinly traded nano cap VistaGen Therapeutics ( OTC:VTGN -44.8% ) slumps on almost a 5x surge in volume in reaction to the  unsuccessful outcome of an exploratory Phase 2 clinical trial assessing lead candidate AV-101 as monotherapy in patients with treatment-resistant depression. M...

VTGN - ABMD, FLR and W among premarket losers

Eventbrite (NYSE: EB )  -34%  on Q1 earnings . More news on: Eventbrite, Inc., VistaGen Therapeutics, Inc., ABIOMED, Inc., Stocks on the move, Read more ...

VTGN - VistaGen Reports Top Line Results from NIMH's Exploratory Study of AV-101 Monotherapy for Treatment-Resistant Depression

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / May 2, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unmet n...
VTGN - VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 3, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and disorders with high unmet need, today announced tha...

VTGN - Positive Pilot Phase 3 Data Position VistaGen's PH94B Neuroactive Nasal Spray for Pivotal Phase 3 Development as a Novel, As-Needed Treatment for Social Anxiety Disorder

PH94B has potential to be the First FDA-Approved PRN Treatment for Social Anxiety Disorder New Findings Presented at the 2019 Anxiety and Depression Association of America Annual Conference SOUTH SAN FRANCISCO, CA / ACCESSWIRE / April 1, 2019 / VistaGen Therapeutics (NASDAQ: VTGN...

VTGN - VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101

SOUTH SAN FRANCISCO, CA / ACCESSWIRE / March 28, 2019 / VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression, social anxiety disorder and other central nervous system (CNS) diseases and disorders with high unm...
Previous 10 Next 10